Astrana Health, Inc. quarterly report, Q3 FY2013

Business context and reporting period

The supplied filing is Apollo Medical Holdings, Inc.’s unaudited Form 10-Q for the quarter ended October 31, 2012, filed December 17, 2012. This differs from the request metadata naming Astrana Health, Inc. The report covers the three and nine months ended October 31, 2012, compared with the same periods in 2011.

Apollo managed hospitalist, pulmonary/critical-care, and other physician services, primarily in California. In July 2012, its ACO was selected to participate in Medicare’s Shared Savings Program. The company said it was building infrastructure for this initiative and expected substantial upfront investment.

Key financial results

Quarterly revenue rose 37.2%; management attributed the increase to Verdugo consolidation and growth in fee-for-service work, including new hospital contracts and expanded services. Nine-month revenue increased 47.2%. Despite revenue growth, quarterly gross margin contracted sharply: cost of services was 91.5% of revenue, versus 76.6% a year earlier. Management cited higher physician costs and noncash stock compensation. Nine-month cost of services was 82.6% of revenue, versus 83.9%.

Operating expenses included substantial noncash compensation: management attributed $1.48 million of the quarter’s year-over-year operating-result decline to increased noncash stock compensation. General and administrative expense was $1.60 million for the quarter, including $1.08 million of noncash stock compensation. Net losses also reflected fair-value charges on warrant and derivative liabilities of $3.06 million for the quarter and $5.85 million for the nine months, as well as higher interest and financing costs.

Liquidity, debt and balance sheet

• Cash and cash equivalents were $500,964 at October 31, 2012, up from $164,361 at January 31, 2012. Current assets were $2.01 million and current liabilities $1.21 million.
• Total assets were $2.17 million; total liabilities were $2.25 million. Stockholders’ deficit was $78,587, and accumulated deficit was $10.20 million.
• Debt at October 31 included a $500,000 senior secured note and $1.19 million of convertible-note principal ($1.036 million carrying value after debt discount); reported total gross debt was $1.90 million and net carrying debt $1.54 million.
• Operating cash flow was positive despite the net loss, principally because of substantial noncash charges. Financing cash flow was $130,000: $500,000 of note proceeds was partly offset by $370,000 distributed to a noncontrolling-interest shareholder.

Material changes, outlook and risks

• Going concern: Management said losses could continue through fiscal 2013, that liquidity might be insufficient for the next 12 months, and that substantial doubt existed about the company’s ability to continue as a going concern. It planned to seek additional capital through equity, debt, partnerships, joint ventures, asset sales, or other sources, with no assurance of success; failure to raise capital in time could force cessation of operations.
• ACO investment: Management expected substantial upfront funding needs over the next 18–24 months and said there was no assurance the ACO would be profitable or adequately funded. No numerical earnings or revenue guidance was provided.
• Debt amendments and unusual accounting: In October, the 10% convertible notes’ maturity was extended to January 2016 and their conversion price fixed at $0.11485; related conversion and warrant liabilities were reclassified to equity. The company reported sizeable fair-value losses before that reclassification. The senior secured note was amended, with deferred principal payments and maturity extended to October 2013.
• Equity compensation and dilution: The company issued 4.22 million common shares during the quarter and granted options and warrants. At quarter-end, 34.77 million common shares were outstanding; the filing also lists significant potential shares from convertible notes, warrants, and options.
• Customer concentration: The largest customer accounted for 20.8% of quarterly revenue and 24.0% of nine-month revenue. The filing identifies three major customers but does not name them in the supplied text.
• Controls and contingencies: Management concluded disclosure controls were ineffective and identified material weaknesses in written control documentation, segregation of accounting duties, and financial-reporting review and supervision. The company described ordinary-course legal matters, including medical-malpractice claims, and said it did not expect them to have a material adverse effect, while noting outcomes were uncertain.

Most important facts for investors to verify

• Confirm the filing identity: the source is for Apollo Medical Holdings, Inc., not the company named in the request metadata.
• Assess the going-concern warning against available financing, near-term cash needs, and the subsequent December 2012 private-placement offering described in the filing.
• Review note and warrant terms, maturities, conversion prices, collateral, and the accounting behind the large noncash fair-value losses and reclassifications.
• Evaluate whether revenue growth can translate into sustainable margins after physician costs, stock compensation, ACO spending, and administrative costs.
• Track remediation of the disclosed material weaknesses, potential share dilution, customer concentration, and the economics and funding requirements of the MSSP ACO.